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Abstract 
Neurobrucellosis has been reported to cause lesions in a number of different locations in the 
central nervous system. Histologically or radiologically, these lesions were consistent with an 
infection. In response to parents who believed their child’s brain tumor, histologically typical 
of medulloblastoma, was in reality neurobrucellosis, formalin-fixed paraffin-embedded tumor 
tissue from the medulloblastoma was sectioned, DNA extracted, and tested by polymerase 
chain reaction (PCR). Specific primer/probe sets, designed in our laboratory to target Brucella 
species, B. melitensis, B. abortus and B. suis, and designated OMP31, B-m, B-a and B-s, respec-
tively, were used in TaqMan real-time PCR to amplify those gene targets in two separate 
blocks of the child’s tumor. Sections from two blocks were positive only for Brucella species. 
Although the patient grew up in a European country known to harbor brucella in foods, such 
as unpasturized milk and cheese, the patient was seronegative for B. mellitensis, B. suis, and B. 
abortus. In an effort to test whether a relationship existed between the presence of brucella 
and medulloblastoma, 20 medulloblastomas were retrieved from the tissue repository of the 
AFIP. The above four primer/probe sets were again used to amplify brucella DNA. Five of 20 
tumors (25%) contained Brucella species DNA by the OMP31 primer/probe set. None of the 
20 medulloblastomas had specific sequences for B. mellitensis, B. suis, or B. abortus. Is chronic 
brucellosis similar to other infectious agents such as helicobacter that is associated with 
tumor formation? 
Key  words:  brucellosis;  Brucella  sp;  medulloblastoma;  glioblastoma;  Formalin-Fixed  Paraf-
fin-Embedded (FFPE); milk; dairy. 
Introduction 
Medulloblastoma, a primitive neuro-ectodermal 
tumor (PNET) arising in the posterior fossa, is one of 
the  most  common  malignant  tumor  of  the  central 
nervous  system  (CNS)  in  children.  Overall  survival 
for  children  with  non-disseminated  and 
non-anaplastic medulloblastoma can approach 80%.1 
Radiologic  and  histopathologic  features  include  hy-
perattenuation  on  unenhanced  computed  tomo-
graphic  scans  that  reflects  the  high  nucle-
ar-cytoplasmic  ratio  seen  at  histological  analysis.2 
Medulloblastoma  can  also  occur  in  late  middle  age 




in childhood. Studies of chromosomal abnormalities, 
genetic  syndromes,  and  individual  genes  have  con-
tributed to the understanding of medullblastoma bi-
ology.3 
An infectious association with medulloblastoma 
was proposed in 2002. Del Valle et al demonstrated 
the  presence  of  the  human  polyoma  virus  (JCV)  T 
antigen (Tag), and agnoprotein DNA in 65% and 69% 
of  20  and  16  medulloblastoma  FFPE  specimens,  re-
spectively.4 In an accompanying editorial “Polyoma-
virus and Medulloblastoma: A Smoking Gun or Guilt 
By  Association?”  Howard  A.  Fine5  cautioned  “only 
through well-controlled epidemiological case-control 
studies evaluating large numbers of both normal and 
tumor-associated brains for the presence of JCV, will 
we have a chance of determining the relative contri-
bution of the virus toward tumor promotion.” Over 
the  years  PCR  findings  have  not  confirmed  a  viral 
association with medullolastoma.6-9 
Brucellosis  is  caused  by  an  intracellular 
gram-negative coccobacillus and produces lesions in 
multiple  organs  including  the  brain.  Exposure  to 
Brucella species occurs through drinking or eating un-
pasteurized milk products, meat, or contact with in-
fected animals. CNS brucellosis is rare. In a study of 
19 patients in 1987, 8 patients had meningoencephali-
tis,  6  had  proximal  polyradiculoneuritis,  and  5  had 
diffuse  CNS  involvement  (including  one  with  cere-
bellar  involvement).10  In  a  study  of  301  brucellosis 
patients in 1992, 18 had neurobrucellosis, two patients 
exhibited cerebellar dysfunction.11 
In 2009 a 14 year-old girl presented with double 
vision. On MRI examination a 5x3 cm mass was cen-
tered  in  the  fourth  ventricle.  Resection  of  the  mass 
revealed  a  small  blue  cell  tumor  forming  scattered 
Homer-Wright  rosettes,  characteristic  of  classic  me-
dulloblastoma.  Immunohistochemical  staining  ex-
cluded  lymphoma  and  metastases.  Initial  IgM  for 
brucella was 0.78 (<0.50 neg) and IgG was negative. 
Repeat IgM was negative. In response to the parents 
who believed the mass was actually neurobrucellosis, 
the AFIP performed PCR testing for Brucella sp DNA 
in the tumor tissue. Surprisingly DNA extracted from 
two formalin-fixed, paraffin-embedded (FFPE) tissue 
blocks contained a 62 base pair (bp) sequence of DNA 
found  only  in  the  outer  membrane  protein  gene 
(OMP31) of  Brucella species. Specific primers/probes 
for B. melitensis, B. abortus, and B. suis did not produce 
a DNA product from the two tumor blocks. 
In order to assess if brucella may have any asso-
ciation  with  medulloblastoma,  we  retrieved  FFPE 
blocks from brains of patients who died of medullo-
blastoma as well as blocks of brains from patients who 
died with other malignancies in the CNS, and brains 
of  patients  without  evidence  of  CNS  tumors.  This 
study showed an unexpected presence of Brucella sp in 
FFPE CNS tissues from patients who died from ma-
lignancy in the brain. 
Materials and Methods 
Clinical Samples 
 A total of 52 FFPE autopsy samples of brain tis-
sues were collected from the pathology archives of the 
Armed Forces Institute of Pathology. Thirty-one had 
evidence of malignancy, 21 were without evidence of 
malignancy. Of the 31, 20 were diagnosed as medul-
loblastomas, 5 as glioblastoma, 4 as metastatic carci-
noma and 2 with leukemia. 
DNA retrieval from FFPE sections  
Fifty-two  FFPE  blocks  were  cut  with  a  micro-
tome  (5  µm  in  thickness,  3  sections  per  block).  All 
cut-sections were collected into separate DNase-free 
Eppendorf tubes and processed for DNA retrieval as 
follows: (i) de-paraffinized by treatment with 800 µl of 
xylene (twice) followed by removing xylene with 800 
µl of pure ethanol treatment (twice); (ii) tissue diges-
tion  and  nucleic  acids  separation  were  carried  out 
following a modified protocol of a QIAGEN Kit (Cat# 
51106); (iii) RNA cleaning by incubation samples at 
37oC  for  30  minutes  with  RNase  A  (100  mg/ml, 
QIAGEN) and (iv) DNA was purified by QIAquick 
column (washing buffer 1 and 2, QIAGEN). The final 
DNA samples were eluted off the columns in 30 µl of 
elution buffer (QIAGEN), followed by quantification 
with  ND-1000  Spectrophotometer  (NanoDrop).  All 
DNA  samples  were  stored  at  -20oC  for  later  usage. 
Before use the DNA concentration was adjusted be-
low 150 ng/µl.  
TaqMan PCR primers and probes  
Four sets of TaqMan primers and probes were 
designed for identification of Brucella at species level 
(set  1  -  3)  or  at  genus  level  (set  4).  Brucella  spe-
cies-specific assays for B-m, B-a and B-s targets were 
determined  by  selecting  the  insertion  sequences 
(IS711 elements)12 in the genome of Brucella melitensis 
(Region  1209562…1209713,  AE008917.1),  B.  abortus 
(701208…701381,  AM040265.1),  and  B.  suis 
(1618822…1618948,  AE014291.4),  respectively.  The 
amplicon length in each primer set ranged from 127 to 
174 bp, and each amplicon was checked  in silico by 
BLAST  alignment  program.  The  OMP31  primer  set 
(set 4) was developed to amplify Brucella OMP31gene 
target  (31  KDa  outer  membrane  protein)  (Locus: 
BruAb1_1608;  Region  1586489…1587274;  AE017223). 
All  primers  were  designed  with  Primer  Express 




nucleotides in the OMP31 gene fragment was ampli-
fied with primer GGCTCGGTTGCCAATATC (f) and 
GACTGCGTAAAGCCGGACTC  (r).  A  TaqMan  hy-
drolysis  probe  FAM-tgcgatcaagtcgggcgctct-TAMRA, 
designed by using the same software, hybridizes with 
the  specific  amplicon  as  shown  by  an  in silico PCR 
amplification.13 The 62-bp fragment demonstrated a 
broad  range  of  alignment  with  Brucella  species.  All 
primer  oligos  were  ordered  from  Integrated  DNA 
Technology (IDT), and TaqMan probes from ABI.  
Validation of TaqMan real-time PCR assays and 
amplification conditions  
Validation tests of each assay were carried out by 
testing  standard  Brucella  DNA,  extracted  from  cul-
ture of B. melitensis 16M strain. Bacterial culture was 
conducted in a BSL-3 laboratory at the AFIP. Standard 
DNA  serial  dilutions  (10-fold)  were  from  200 
picogram (pg) to 200 femtogram (fg) per microliter. A 
specificity  DNA  panel  was  prepared  by  collecting 
DNA samples from cultures of Brucella sp (Table 1), 
near neighbors and other bacteria (not shown).  
 
Table 1. Brucella DNA Panel Tested by TaqMan Primer / 
Probe Sets 
Organisms  B-m  B-a  B-s  Omp31 
B. abortus    -  +  -  + 
B. cetacae  -  -  -  + 
B. maris  -  -  -  + 
B. melitensis (16M)  +  -  -  + 
B. melitensis(349CA)  +  -  -  + 
B. pinnipedia  -  -  -  + 
B. canis  -  -  -  + 
B. ovis  -  -  -  + 
B. suis  -  -  +  + 
B. microti  -  -  -  + 
 
 
The  validation  results  demonstrated  that  the 
limitation of detection (LoD) of these real-time PCR 
assays is around 50 fg, equivalent to 5 Brucella ge-
nomes. The calculation was performed according to 
Brucella genome size (B. melitensis, 16M str., 2.12 Mb) 
and  a  real-time  PCR  standard  amplification  curve 
(data  not  included).  Specificity  tests  confirmed  no 
cross-species amplification among primer set 1 to 3; 
OMP31  primers  amplified  all  Brucella  DNAs  in  the 
DNA panel. TaqMan real-time PCR reaction was car-
ried out in a LightCycler (Software 4.1, Roche). In PCR 
assay,  each  capillary  (20  µl)  contained  10X  buffer 
(with  50  mM  MgCl2,  IT),  dNTPs  (2  mM  each,  IT), 
TaqMan primers (300 nM each), probe (50 nM), Taq 
polymerase  (1  unit,  Invitrogen)  and  5  µl  of  DNA 
samples.  Cycle  conditions  were  as  follow:  Reaction 
capillary  was  incubated  at  95ºC  for  2  minutes,  fol-
lowed by 40 cycles of two-step amplification: 95ºC for 
zero seconds and 60ºC for 20 seconds.  
Results 
The  association  of  brain  tumors,  medulloblas-
toma as an example, with the presence of a Brucella 
species DNA has not been previously addressed. Par-
ents of a patient with medulloblastoma however, in-
sisted that Brucella was associated with their child’s 
brain  tumor.  This  prompted  us  to  investigate  the 
presence of Brucella sp DNA in medulloblastoma tu-
mor tissues. These samples represent different histo-
logic presentations, classic, anaplastic, nodular, large 
cell,  and  included  samples  with  the  more  general 
terminology  primitive  neuro-ectodermal  tumor 
(PNET).  
 After  finding  the  child’s  medulloblastoma  did 
contain  Brucella sp DNA, we asked members of the 
Department of Neuropathology to retrieve brain tu-
mors, especially medulloblastoma from the archives. 
In Table 2, 20 brain specimens diagnosed as medullo-
blastoma were tested for Brucella sp DNA. Five (25%) 
patients’  tissues  were  positive  only  for  the  outer 
membrane protein gene (OMP31). All were male, ages 
ranged from 4 to 24, average 13.8 years. All died in the 
United  States  of  America.  Fifteen  (75%)  patients’ 
medulloblastoma  tissues  contained  no  OMP31  gene 
sequences.  These  15  patient’s  ages  ranged  from  6 
months to 27 years, average 12.5 years. Three patients 
died in Europe and 12 died in the United States. None 
of the 20 cases contained specific sequences related to 
B. melitensis, B. abortus, or B. suis.  
 In order to determine if Brucella sp DNA is pre-
sent in the brain of patients dying of non-malignant 
disorders, 21 brain samples were retrieved and tested 
for Brucella sp specific DNA sequence (OMP31 gene 
fragment). One patient (4.8%) (#15 Table 3) who died 
with changes consistent with his diagnosis of spino-
cerebellar ataxia had Brucella sp DNA in his brain tis-
sue. The remaining 20 had no identifiable Brucella sp 
DNA sequences. The male to female ratio of the 21 
patients was 4:1, average age 53.3 years. 
 Brain  tissues  from  11  patients  diagnosed  with 
other  malignancies  were  also  examined  using  the 
OMP31 primer/probe set (Table 4). Four of 11 con-
tained Brucella sp DNA sequences, in which three of 
five (60%) of brains diagnosed as glioblastoma, 1 of 4 
brains  (25%)  with  the  histologic  diagnosis  of  meta-
static carcinoma, and neither of the two brains with a 
diagnosis of leukemia demonstrated Brucella sp DNA 




 In summary, 10 of the 52 (19%) brain tissues re-
trieved from the archival files of AFIP contained Bru-
cella sp DNA (outer membrane protein –OMP31 gene 
fragment). Specific Brucella sp DNA was identified in 
25% of the medulloblastomas, 60% of the glioblasto-
mas, and 25% of the metastatic carcinomas. 
 
Table 2. Evidence of Brucella sp DNA in 20 who died of medulloblastoma related tumors 
Patient 
(No) 
PCR (+/-)  Age (yrs)  M/F  Diagnoses 
1  -  0.5  F  PNET with astrocytic differentiation 
2  -  1  F  PNET with glial differentiation 
3  +  4  M  Medulloblastoma 
4  -  5  M  Anaplastic with rare nodules 
5  -  6  F  Large cell medulloblastoma 
6  +  7  M  Medulloblastoma 
7  -  8  M  PNET/medulloblastoma 
8  -  8  M  Nodular medulloblastoma 
9  -  9  M  Anaplastic medulloblastoma 
10  -  9  M  Medulloblastoma 
11  +  12  M  Classic Medulloblastoma 
12  -  13  F  Medulloblastoma 
13  -  14  M  Anaplastic/classic medulloblastoma 
14  -  18  F  PNET 
15  -  21  M  Classic medulloblastoma 
16  +  22  M  Medulloblastoma 
17  -  22  M  Anaplastic medulloblastoma 
18  +  24  M  Medulloblastoma 
19  -  26  F  Anaplastic medulloblastoma 
20  -  27  M  Medulloblastoma 
 
Table 3 Evidence of Brucella sp DNA in CNS of twenty-one without evidence of malignancy 
Patient 
(No) 
PCR (+/-)  Age (yrs)  M/F  Diagnoses 
1  -  0.5  F  Nonspecific changes 
2  -  0.5  M  Acute hypoxic ischemic neuronal injury 
3  -  9  M  Vascular malformation; subarachnoid hemorrhage 
4  -  26  F  Minimal histological changes 
5  -  26  M  Acute hypoxic ischemic neuronal injury 
6  -  37  F  Arteriolar sclerosis 
7  -  49  M  Nonspecific changes 
8  -  55  M  Arteriolar sclerosis 
9  -  56  M  Reactive change; arteriolar sclerosis 
10  -  62  M  Alzheimer disease; amyloid angiopathy 
11  -  66  M  Hepatitis, seizures 
12  -  68  M  Dementia with Lewy bodies 
13  -  69  M  Chronic infarction; arteriolar sclerosis 
14  -  71  M  Hemorrhagic stroke 
15  +  72  F  Changes of spinocerebellar ataxia; amyloid angiopathy 
16  -  74  M  Ascites & chronic infarctions 
17  -  74  M  Arteriolar sclerosis; atherosclerosis 
18  -  77  M  Neurodegenerative changes 
19  -  86  M  Alzheimer disease; amyloid angiopathy 
20  -  88  M  Neurodegenerative changes 





Table 4. Evidence of Brucella sp DNA in CNS of 11who died of non-medulloblastoma malignancies 
Patient 
(No) 
PCR (+/-)  Age (yrs)  M/F  Diagnosis 
1  -  3  F  Glioblastoma 
2  +  38  F  Glioblastoma 
3  +  48  M  Metastatic small cell carcinoma 
4  -  52  F  Glioblastoma 
5  +  56  M  Glioblastoma 
6  +  62  M  Glioblastoma 
7  -  66  M  Metastatic small cell carcinoma 
8  -  69  M  Myeloid leukemia 
9  -  75  M  Metastatic poorly differentiated carcinoma 
10  -  79  M  Metastatic squamous cell carcinoma 





 The idea of a Brucella species or the disease bru-
cellosis  being  associated  with  brain  tumors,  specifi-
cally  medulloblastoma  or  glioblastoma  must  be  ad-
dressed with caution. Howard A. Fine’s words out-
lining the need for a “well-controlled epidemiological 
case-control study evaluating large numbers of both 
normal and tumor-associated brains” in the sugges-
tion that JC virus was associated with medulloblas-
toma formation exactly outlines the tasks necessary to 
affix any role of brucellosis in patients who develop 
medulloblastomas or other brain tumors.  
 There  are  several  problems  in  collecting  suffi-
cient material to conduct a full study. The first is the 
number of cases available with FFPE tissue blocks. We 
were  only  able  to  obtain  material  from  20  patients 
with medulloblastoma. The second is using the opti-
mal  size  primer/probe  sets.  Sensitive  and  specific 
PCR primers are crucial for accurate characterization 
of disease biomarkers in FFPE tissue. In primer de-
signing, if amplicon size is longer than 200 bp, PCR is 
often unsuccessful.14,15 We used Primer Express Soft-
ware (v 3.0) for designing all TaqMan assay primers 
and  probes.  The  software  generates  amplicons  of 
smaller size, usually between 60 to 150 bp, that just 
fits  the  amplification  of  FFPE  DNA  fragments.  As 
shown  in  Table  1,  the  OMP31primer  set  amplifies 
Brucella sp as opposed to near neighbors. The resulting 
PCR amplicon  [GGCTCGGTTGCCAATATCAATGC 
GATCAAGTCGGGCGCTCTGGAGTCCGGCTTTAC
GCAGTC] only aligned with Brucella species (100% 
identity)  on  Blast  search.  The  third  problem  is  the 
necessity to guard against DNA contamination in the 
cutting,  extraction,  and  real-time  PCR  amplification 
processes.  The  ideal  study  would  be  conducted  at 
separate sites using identical primer/probe sets. 
 Is  there  any  evidence  that  bacteria  or  bacte-
ria-like agents can be implicated in cancer formation? 
One bacterial species has been shown to have an as-
sociation  with  cancer.  Gastric  cancer  develops  in 
persons  infected  with  Helicobacter  pylori  but  not  in 
uninfected  persons.16  One  bacteria-like  agent  Myco-
plasma fermentans has been shown in the laboratory to 
induce a Mycoplasma-mediated multistage malignant 
transformation  of  cultured  mouse  embryo  cells 
(C3H).17 
 Positive DNA findings for Brucella species in our 
index  patients  focused  our  attention  on  studying 
medulloblastomas,  as  shown  in  this  index  patient, 
serological  examination  and  cultures  for  brucellosis 
were  non-contributory.  This  might  mean  that  live 
Brucella sp organisms are not present, only Brucella sp 
DNA. In the United States, people drink pasteurized 
milk and milk products and eat meats from antibiotic 
treated animals. Is it possible that the source of the 
detected Brucella sp DNA was denatured DNA from 
diet,  not  from  an  active  Brucella sp  infection?  More 
studies  would be  needed  to further investigate any 
true association between  Brucella sp  DNA positivity 
and CNS tumor formation. 
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